Adamax

Adamax (Ac-MEHFPGPAG-NH₂, where the N-terminal acetyl group bears an adamantane cage) is a structurally enhanced analogue of Semax — sharing the same core heptapeptide sequence (Met-Glu-His-Phe-Pro-Gly-Pro, the ACTH(4-10) fragment with C-terminal Pro-Gly-Pro stabilization) but with two critical modifications: an N-terminal adamantane acetylation replacing Semax's standard acetyl cap, and a C-terminal amidation (Semax terminates as the free acid). Both modifications target the same problem — rapid enzymatic degradation — through complementary mechanisms that together produce a dramatically more stable and CNS-penetrant peptide.

The adamantane modification is the key innovation. Adamantane is a rigid, highly lipophilic diamondoid cage structure (tricyclo[3.3.1.1³'⁷]decane) that, when attached to the N-terminus, creates a bulky hydrophobic shield that sterically blocks aminopeptidase access to the peptide backbone. Simultaneously, the adamantane's lipophilicity dramatically increases blood-brain barrier permeability — the same property that makes adamantane-containing drugs (amantadine, memantine) effective CNS agents. The C-terminal amidation provides complementary protection against carboxypeptidase degradation at the opposite end of the molecule. Together, these modifications extend Adamax's CNS residence time and receptor occupancy well beyond Semax's, producing sustained neurotrophic signaling from less frequent or lower dosing.

Mechanistically, Adamax targets the same pathways as Semax — BDNF/TrkB upregulation driving hippocampal neuroplasticity, synaptic strengthening, and neuroprotection — but with greater potency and duration. Enhanced BDNF expression promotes dendritic arborization, long-term potentiation (LTP), and neuronal survival under oxidative and ischemic stress. The peptide also modulates dopaminergic and serotonergic neurotransmission, contributing to effects on focus, motivation, and cognitive endurance. Adamax additionally influences enkephalinase inhibition (prolonging endogenous opioid peptide half-life), a mechanism shared with Semax that may contribute to mood stabilization and stress resilience. The adamantane group itself may have independent neurotropic activity — adamantane derivatives are known NMDA receptor modulators — though this has not been formally characterized for Adamax specifically.

Adamax is a relatively recent addition to the Semax-derived nootropic peptide family, developed as a rational medicinal-chemistry optimization of Semax's known limitations — short CNS half-life and moderate BBB penetration. The design strategy borrowed from the successful clinical history of adamantane-containing drugs: amantadine (influenza, Parkinson's disease) and memantine (Alzheimer's disease) both use adamantane cages to achieve CNS penetration and target residence time.

Published research on Adamax specifically is extremely limited compared to Semax, which has over 300 publications and decades of Russian clinical use. Most Adamax information derives from structural pharmacology, in vitro BDNF assays, and anecdotal nootropic-community reports rather than formal clinical trials. The compound is sometimes conflated with "N-Acetyl-Semax" in commercial contexts, though N-Acetyl-Semax is a distinct analogue (Semax with an additional N-terminal acetyl group, no adamantane). Adamax occupies an interesting position: a rationally designed Semax analogue with plausible pharmacokinetic advantages, supported by structural logic and mechanistic extrapolation from the well-characterized parent peptide — but with a thin direct evidence base that researchers should weigh accordingly.

Store lyophilized Adamax at -20°C in a tightly sealed, desiccated, light-protected container. The adamantane-capped structure provides significant stability advantages — the N-terminal adamantane cage blocks aminopeptidase access, and the C-terminal amide resists carboxypeptidases. These same features that improve in vivo half-life also improve shelf stability. Expected stability exceeds 24 months under optimal conditions.

After reconstitution with bacteriostatic water, Adamax should be stored at 2–8°C and used within 28 days — the longer window compared to standard peptides reflects the enhanced enzymatic stability conferred by the terminal modifications. The adamantane group increases lipophilicity; ensure the solution is clear before use. Some protocols report a slightly longer dissolution time compared to Semax — swirl gently for 60–90 seconds. Protect from light. Do not freeze reconstituted solutions. For intranasal protocols using sterile saline, use within 14 days.